Scholar Rock reports first ISEMBYLD sales, agrees to sell $205 million PRVNov 10Quarterly updateapitegromab-mstnScholar Rock, Inc.
Scholar Rock corrects statement on FDA conditions for ISEMBYLD approvalSep 15Regulatory decisionapitegromab-mstnScholar Rock, Inc.
Sign inSign in